Get Involved

Help make a difference in the lives of those with autoimmune disease.

What is Autoimmune Disease?
- AUTOIMMUNE VS AUTOINFLAMMATORY DISEASE
  
  A Comparative Look
  
  Autoimmune disease (AD) and autoinflammatory disease (AIF) are two categories of illnesses that occur when the immune system mistakenly damages healthy cells. Although these inflammatory disorders share many commonalities, there are key features that make them unique.
  Read Our Article
  Autoimmune diseases (AD) occur when the immune system attacks the body’s own healthy cells. There are 80-100 known autoimmune diseases and counting, affecting more than 14 million Americans.
  AUTOIMMUNE VS AUTOINFLAMMATORY DISEASE
  
  A Comparative Look
  
  Autoimmune disease (AD) and autoinflammatory disease (AIF) are two categories of illnesses that occur when the immune system mistakenly damages healthy cells. Although these inflammatory disorders share many commonalities, there are key features that make them unique.
  
  Read Our Article
Resources & Support
- FREE RESOURCE
  
  Find Hope in Your Health Journey
  
  The Autoimmune & Chronic Illness Toolkit includes journal templates, resource lists, guidance for doctor appointments, tips on communication, and many more tools to support and empower you throughout your experience.
  Get Our Guide
  Browse our resource lists and information via the links below.
  FREE RESOURCE
  
  Find Hope in Your Health Journey
  
  The Autoimmune & Chronic Illness Toolkit includes journal templates, resource lists, guidance for doctor appointments, tips on communication, and many more tools to support and empower you throughout your experience.
  
  Get Our Guide
Education & Research
- HIGHLIGHTED PARTNERSHIP
  
  GAI is proud to fund the Raising Celiac podcast from the Celiac Disease Program at Boston Children’s Hospital
  
  Each episode features education, awareness and research on celiac disease in connection with other autoimmune conditions, including expert interviews on how these autoimmune diseases co-exist.
  View Podcast
  We support autoimmune disease research, awareness, and education. We fund clinical research, scientific investigations, multidisciplinary medicine, and educational resources, including podcasts and webinars.
  HIGHLIGHTED PARTNERSHIP
  
  GAI is proud to fund the Raising Celiac podcast from the Celiac Disease Program at Boston Children’s Hospital
  
  Each episode features education, awareness and research on celiac disease in connection with other autoimmune conditions, including expert interviews on how these autoimmune diseases co-exist.
  
  View Podcast
About Us
- SPREADING AWARENESS
  
  We were proud to sponsor Nature Magazine’s July 2021 Outlook on Autoimmune Disease
  
  Learn more about GAI's work, autoimmune risk factors, research advances, and more!
  Read Our Feature
  The Global Autoimmune Institute is empowering solutions in the diagnosis and treatment of autoimmune disease (AD) through research, education, and validation while supporting multidisciplinary approaches to wellness.
  SPREADING AWARENESS
  
  We were proud to sponsor Nature Magazine’s July 2021 Outlook on Autoimmune Disease
  
  Learn more about GAI’s work, autoimmune risk factors, research advances, and more!
  
  Read Our Feature
Search

Clinical Trials

Dose 3 Adverse Reactions Similar to Dose 2

October 1, 2021

This morning, the CDC released their Morbidity and Mortality Weekly Report focusing on third doses of the COVID-19 vaccine. The report referenced Pfizer’s Phase 3 clinical trial, which included 306 participants, ages 18-55, who received a booster dose. Doses were administered 5-8 months after completion of a primary series using mRNA vaccines. Adverse reactions were similar to those after the second dose, and “included mild to moderate injection site and systemic reactions” (1).

WHO Endorses Regeneron’s COVID-19 Antibody Treatment

September 27, 2021

Last Friday, the WHO endorsed the use of Regeneron’s monoclonal antibody cocktail for patients at high risk of being hospitalized due to severe COVID-19. Others eligible for treatment include those unable to develop antibodies to COVID-19, through previous infection or vaccination. This includes immunocompromised persons. Regeneron’s casirivimab and imdevimab antibody cocktail, administered by infusion, was the first combination therapy to receive FDA EUA.

NIH Launches Clinical Trial Studying COVID Booster Response in Autoimmune Disease Non‐Responders

September 1, 2021

Earlier this week, the NIH announced that they are launching a new clinical trial to determine the antibody response of a booster dose in autoimmune disease patients who did not respond to an initial full dose of the COVID-19 vaccine.

Using Infliximab to Treat COVID

August 12, 2021

Yesterday, the WHO announced that three drugs are being tested as effective treatments for COVID-19. The trial will include infliximab, which is currently approved to treat autoimmune diseases such as Crohn’s disease, ulcerative colitis, psoriatic arthritis, and rheumatoid arthritis.

<< 1 2 3 4 5 … 9 >>